NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
David S. Ettinger(Johns Hopkins University), Miranda Hughes(National Comprehensive Cancer Network), Jules Lin(University of Michigan), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Billy W. Loo(Princess Margaret Cancer Centre), Wallace Akerley(University of Utah), Jessica R. Bauman, Stephen C. Yang(Johns Hopkins University), Rudy P. Lackner(Susan Thompson Buffett Foundation), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Ankit Bharat(Northwestern University), Daniel Morgensztern(Barnes-Jewish Hospital), Aparna Hegde(University of Colorado Cancer Center), Douglas E. Wood(University of Washington), Dara L. Aisner(University of Colorado System), Matthew A. Gubens(University of California, San Francisco), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Steven E. Schild(Mayo Clinic Hospital), Michael Lanuti(Massachusetts General Hospital), Alda L. Tam(The University of Texas MD Anderson Cancer Center), Sandip Pravin Patel(University of California San Diego), Scott Gettinger(Yale Cancer Center), Christine M. Lovly(Dana-Farber Cancer Institute), Theresa A. Shapiro(Sidney Kimmel Comprehensive Cancer Center), Lucian R. Chirieac(Mount Sinai Hospital), Thomas J. Dilling(Moffitt Cancer Center), Jonathan E. Dowell(Southwestern Medical Center), Aditi P. Singh(University of Nevada, Las Vegas), Thomas Ng(University of Tennessee Health Science Center), Renato Martins(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mark Hennon(Roswell Park Comprehensive Cancer Center), Thomas A. D’Amico(General Marble (Greece)), Kristina M. Gregory(National Comprehensive Cancer Network), Débora S. Bruno(University Hospitals Cleveland Medical Center), Jane Yanagawa(University of California, Los Angeles), James Stevenson(Cleveland Clinic), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 1,006
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k